Pranlukast, a cysteinyl leukotriene receptor 1 antagonist, attenuates allergen-specific tumour necrosis factor alpha production and nuclear factor kappa B nuclear translocation in peripheral blood monocytes from atopic asthmatics

Clinical and Experimental Allergy

Volumn 33, Issue 6, 2003, Pages 795-801

  Tomari, S ^a   Matsuse, Hiroto ^a   Machida, I ^a   Kondo, Y ^a   Kawano, T ^a   Obase, Y ^a   Fukushima, C ^a   Shimoda, T ^a   Kohno, S ^a  

^a NAGASAKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Atopic asthma; Leukotriene; NF B; Pranlukast; TNF

Indexed keywords

CYSTEINYL LEUKOTRIENE RECEPTOR 1 ANTAGONIST; DEXAMETHASONE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PRANLUKAST; RECEPTOR BLOCKING AGENT; TACROLIMUS; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADULT; ALLERGIC ASTHMA; ARTICLE; BLOOD; CELL NUCLEUS TRANSPLANTATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DERMATOPHAGOIDES FARINAE; DRUG EFFECT; FEMALE; HUMAN; HUMAN CELL; LOW DRUG DOSE; MALE; MEDIATOR RELEASE; MONOCYTE; PRIORITY JOURNAL; SENSITIZATION;

ADULT; ALLERGENS; ANTIGENS, DERMATOPHAGOIDES; ASTHMA; CELLS, CULTURED; CHROMONES; CYTOKINES; DERMATOPHAGOIDES FARINAE; DEXAMETHASONE; FEMALE; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LEUKOCYTES, MONONUCLEAR; LEUKOTRIENE ANTAGONISTS; MALE; NF-KAPPA B; TACROLIMUS; TRANSLOCATION, GENETIC; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0037699908     PISSN: 09547894     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2222.2003.01656.x     Document Type: Article

References (38)

1. Barnes PJ. Cytokines as mediators of chronic asthma. Am J Respir Crit Care Med 1994; 150 (Suppl.):S42-9.
2. Barnes PJ, Churg KF, Adcock IA. Cytokine regulation of chronic inflammation in asthma. In: Holgate ST, ed. Immunopharmacology of the Respiratory Tract. London: Academic Press, 1995; 101-22.
3. Baldwin AS Jr. The transcription factor NF-κB and human disease. J Clin Invest 2001; 107:3-6.
4. Tak PP, Firestein GS. NF-κB: a key role in inflammatory diseases. J Clin Invest 2001; 107:7-11.
5. Hart LA, Krishnan VL, Adocock IM, Barnes PJ, Churg KF. Activation and localization of transcription factor, nuclear factor-κB, in asthma. Am J Respir Crit Care Med 1998; 158:1585-92.
6. Bochner BS, Undem BJ, Lichtenstein LM. Immunological aspects of allergic asthma. Annu Rev Immunol 1994; 12:295-335.
7. Christman JW, Sadikot RT, Blackwell TS. The role of nuclear factor-κB in pulmonary diseases. Chest 2000; 117:1482-7.
8. Barnes PJ, Karin M. Nuclear factor-κB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 1997; 336:1066.
9. Ten RM, McKinstry MJ, Bren GD, Paya CV. Signal transduction pathways triggered by the FcεRIIb receptor (CD23) in human monocytes lead to nuclear factor-κB activation. J Allergy Clin Immunol 1999; 104:376-87.
10. Ten RM, McKinstry MJ, Trushin SA, Asin S, Paya CV. The Signal transduction pathway of CD23 (FcεRIIb) targets IκB kinase. J Immunol 1999; 163:3851-7.
11. National Institutes of Health. Guidelines for the Diagnosis, Management of Asthma. Expert Panel Report II NIH publication no. 97-4051A. Bethesda, MD, NIH, 1997.
12. Global Initiative For Asthma. Revised Pocket Guide For Asthma Management and Prevention. NIH Publication no. 02-3659. Bethesda, MD, NIH, 2002.
13. Taniguchi Y, Tamura G, Honma M et al. The effect of an oral leukotoriene antagonist, ONO-1078, on allergen-induced immediate bronchoconstriction in asthmatic subjects. J Allergy Clin Immunol 1993; 92:507-12.
14. Manning PJ, Watson RM, Margolskee DJ, Williams VC, Schwartz JL, O'Bryne PM. Inhibition of exercise-induced bronchoconstriction by MK-571, a potent leukotriene D4-receptor antagonist. N Engl J Med 1990; 323:1736-9.
15. Spector SL, Smith LJ, Glass M, the ACCOLATE Asthma Trialists Group. Effects of 6 Weeks of therapy with oral doses of ICI 204, 219 a leukotoriene D4 receptor antagonist, in subjects with bronchial asthma. Am J Respir Crit Care Med 1994; 150:618-23.
16. 2-agonist therapy in asthma. Am J Respir Crit Care Med 2001; 164:923-32.
17. Evans DJ, Taylor DA, Zetterstrom O, Chung KF, O'Connor BJ, Barnes PJ. A comparison of low-dose inhaled budesonide plus theophylline and high-dose inhaled budesonide for moderate asthma. N Engl J Med 1997; 337:1412-9.
18. Bentry AM, Hamid Q, Robinison DS et al. Prednisolone treatment in asthma: reduction in the numbers of eosinophils, T cells, tryptase-only positive mast cells, and modulation of IL-4, IL-5 and interferon-γ cytokine gene expression within the bronchial mucosa. Am J Respir Crit Care Med 1996; 153:551-6.
19. Sousa AR, Poston RN, Lane SJ, Narhosteen JA, Lee TH. Detection of GM-CSF in asthmatic bronchial epithelium and decrease by inhaled corticosteroids. Am J Respir Crit Care Med 1993; 147:1557-61.
20. Henderson WR Jr, Tang LO, Chu SJ et al. A role for cysteinyl leukotrienes in airway remodeiing in a mouse asthma model. Am J Respir Crit Care Med 2002; 165:108-16.
21. Tohda Y, Nakahara H, Kubo H, Haraguchi R, Fukuoka M, Nakajima S. Effects of ONO-1078 (pranlukast) on cytokine production in peripheral blood mononuclear cells of patients with bronchial asthma. Clin Exp Allergy 1999; 29:1532-6.
22. Yamamoto Y, Gaynor RB. Therapeutic potential of inhibition of the NF-κB pathway in the treatment of inflammation and cancer. J Clin Invest 2001; 107:135-42.
23. Lee JI, Burckart GJ. Nuclear factor kappa B. Important transcription factor and therapeutic target. J Clin Pharmacol 1998; 38:981-93.
24. Renard P, Ernest I, Houbion A; Calvez HL, Raes M, Remacle J. Development of a sensitive multi-well colorimetric assay for active NF-κB. Nucl Acids Res 2001; 29:E21.
25. Portis T, Harding JC, Ratner L. The contribution of NF-κB activity to spontaneous proliferation and resistance to apoptosis in human T cell leukemia virus type 4 Tax-induced tumors. Blood 2001; 98:1200-8.
26. 2 inhibitors and leukotroene synthesis inhibitors block TNF-induced NF-κB activation. Cytokine 1999; 11:104-10.
27. 2 modulates tumor necrosis factor-α and interleukin-1β induced NF-κB activation. J Biol Chem 2001; 276:30527-36.
28. 24. Am J Respir Cell Moll Biol 2000; 23:572-7.
29. Obase Y, Shimoda T, Tomari S et al. Efficacy and safety of long-term treatment of asthmatic patients with pranlukast, a cysteinyl-leukotriene receptor antagonist: 4-year follow-up study. Ann Allergy Asthma Immunol 2001; 87:43-7.
30. Mita H, Hasegawa M, Saito H, Aldyama K. Levels of cysteinyl leukotriene receptor mRNA in human peripheral leucocytes: significantly higher expression of cysteinyl leukotriene receptor 2 mRNA in eosinophils. Clin Exp Allergy 2001; 31:1714-23.
31. Drazen JM, Yandava CN, Dube L et al. Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatment. Nat Genet 1999; 22:168-70.
32. Oosaki R, Mizushima Y, Kashii T, Kawasaki A, Kobayashi M. Therapeutic effect of pranlukast, a selective cysteinyl leukotriene receptor antagonist, on bronchial asthma. Int Arch Allergy Immunol 1997; 114:97-100.
33. 4-2, 3-dinor-6-keto-prostaglandin (PG)F1α. Allergy 1999; 54:489-94.
34. Tamaoki J, Kondo M, Sakai N et al. Leukotriene antagonist prevents exacerbation of asthma during reduction of high-dose inhaled corticosteroid. Am J Respir Crit Care Med 1997; 155:1235-40.
35. Laviolette M, Malmstrom K, Lu S et al. Montelukast added to inhaled beclomethasone in treatment of asthma. Am J Respir Crit Care Med 1999; 160:1862-8.
36. Christian VJ, Prasse A, Naya I, Summerton L, Harris A. Zafirlukast improves asthma control in patients receiving high-dose inhaled corticosteroids. Am J Respir Crit Care Med 2000; 162:578-85.
37. Tomari S, Shimoda T, Kawano T et al. Effects of pranlukast, a cysteinyl leukotriene receptor 1 antagonist, combined with inhaled beclomethasone in patients with moderate or severe asthma. Ann Allergy Asthma Immunol 2001; 87:156-61.
38. Kohrogi H, Iwagoe H, Fujii K et al. The role of cysteinyl leukotrienes in the pathogenesis of asthma: clinical study of leukotriene antagonist pranlukast for 1 year in moderate and severe asthma. Respirology 1999; 4:319-23.